Andras Guttman, Ph.D., D.Sc., Dr.Habil, Joins eGene's Scientific Advisory Board.IRVINE, CALIF. -- eGene, Inc., (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :EGEI), which is in the business of developing, manufacturing, and marketing bioanalytical systems and reagents for the broad global genomics/genotyping markets, based on its novel CE/Micro-Fluidic Technology Platform, announces the joining of Dr. Guttman to its Scientific Advisory Board. Dr. Udo Henseler, Ph.D., CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , said, "We are exceedingly pleased to welcome Dr. Guttman to eGene's Scientific Advisory Board. His experience and areas of interest in bioanalytical techniques for genomics, proteomics and metabolomics based biomarker discovery Biomarker discovery is the process by which biomarkers are discovered. It is a medical term. Many commonly used blood tests in medicine are biomarkers. The way that these tests have been found can be seen as biomarker discovery. using single- and multi-dimensional separation methods" are indeed a vital resource for eGene. Dr. Andras Guttman is holding a Marie Curie Curie (kürē`), family of French scientists. Pierre Curie, 1859–1906, scientist, and his wife, Marie Sklodowska Curie, 1867–1934, chemist and physicist, b. Chair of the European Commission and leads the recently formed Horvath Laboratory of Bioseparation Sciences (HLBS) at the University of Innsbruck It is currently the largest education facility in the Austrian Bundesland of Tirol and third largest in Austria according to student population, behind Vienna University and Graz University. , Austria. HLBS serves as a Center of Excellence and Training in the Central and Eastern European region to pursue basic research in the field of bioseparation sciences with the aim to develop and implement high performance bioanalytical techniques for genomics, proteomics and metabolomics based biomarker discovery using single- and multi-dimensional separation methods. Prior to joining the HLBS, Dr. Guttman held appointments at Diversa Corporation (San Diego, CA) developing novel separation methods for bioindustrial scale carbohydrate analysis, at the Torrey Mesa Research Institute (La Jolla, CA) on microfluidics, Genetic BioSystems (San Diego, CA), on microgel electrophoresis and Beckman Coulter (Fullerton, CA) on capillary gel electrophoresis. In his postdoctoral work at the Barnett Institute (Boston, MA), he conducted basic research in the field of capillary gel electrophoresis. He has more than 180 scientific publications, edited several textbooks and holds 15 patents. He is an associate director of CASSS and on the editorial boards of numerous international scientific journals. Dr. Guttman graduated from the Veszprem University (Hungary) in chemical engineering, where he also received his Ph.D. He was awarded the Analytical Chemistry Award of the Hungarian Chemical Society in 2000 and became a member of the Hungarian Academy of Sciences The Hungarian Academy of Sciences (in short: HAS, in Hungarian: Magyar Tudományos Akadémia) was founded in 1825, when Count István Széchenyi offered one year's income of his estate for the purposes of a Learned Society in 2004. About eGene, Inc. eGene, Inc. offers low cost, micro-fluidic, miniaturized, digital Genotyping systems, which are critical to the present and future of microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. and biological materials testing applications. The Company's products detect, quantify, identify and characterize micro-organisms at unprecedented specificity and sensitivity, and automate routine and non-routine laboratory and industrial procedures critical to product safety, quality and productivity. For more information, visit eGene's web site at: www.egeneinc.com and view its reports that have been filed with the Securities and Exchange Commission that are contained in the Edgar archives at www.sec.gov. This press release contains forward-looking statements subject to all the risks and uncertainties within the meaning of the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion